The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: NRC-IRAP

FedDev Ontario is Feeding $45 million Through NRC-IRAP to Support SMB Innovation

During a visit to Sernova (TSXV: SVA) today, Gary Goodyear* announced that $45 million of FedDev Ontario money will be deployed through the NRC’s Industrial Research Assistance Program (IRAP). IRAP has been a relatively effective vehicle for funding life science companies and has taken a prominent role since having been allocated $200 million in the 2009 federal [...]

Monday Biotech Deal Review: March 8, 2010

A busy week in Canadian deals, with Paladin Labs in a global transaction with SpePharm; M&A activity from therapeutics and consulting companies; the last of the SIFT/SR&ED deals; over $20 million of new offerings from BioSign, Bradmer and YM; government funding for Medicago and Isotechnika; a new standby equity deal from Yorkville for Allon; and the [...]

Monday Biotech Deal Review: February 15, 2010

A busy Monday Deal Review is headlined by Labopharm and ProMetric on the securities front, MDS’ final divestiture on the M&Eh front and Biovail and Bioniche on the licensing front, and there’s lots more activity behind those for over $100 million of deals.  Check out all the details (and the witty headlines)

Has NRC-IRAP Run Out of 2009 Grant Money?

NRC-IRAP, which got $170 million in the 2009 Federal budget (spread over 2 years) for company funding, has been very active lately, including in biotech. Maybe too active?  I heard rumo(u)rs (plural!) this week that IRAP may be out of funds for this cycle.  Are they? Drop us a line.

NRC-IRAP Is On A Roll: 7 Bio Investments in 7 Weeks

NRC-IRAP,* which got $170 million in Canadian stimulus money, has been deploying funds quite rapidly and has included a significant number of biotechs in its largesse.  I found these from July and August: a $260,000 grant to ImmunoVaccine Technologies Inc.; a $498,500 grant to Opsens Inc. (TSX-V: OPS); an undisclosed amount to Paladin Labs (TSE: PLB); a [...]

Interview With Garrett Herman Yields More Detail on the LOM-BioQuest Joint Venture

We have new details about the LOM-BioQuest joint venture that was announced last week.  The WSJ article about the JV emphasized the goals of supporting good science and expanding the two companies’ presence in the life sciences market. I spoke to the Director of LOM BioQuest, Garrett Herman, and one of his associates yesterday about [...]

Monday Deal Review: July 27, 2009

Well, July is wrapping up with no sign of summer, or of the summer doldrums.  Read on for all the rainy-day deals we found this week

New Data Shows 70% of Canada’s Biotech Companies Have Under 12 Months’ Cash. BIOTECanada’s New Ask: Government Loans.

A Canwest story today highlights new BIOTECanada data showing 70% of survey respondents have under 1 year of cash, up from 50% in January.  FierceBiotech picked it up as well, guaranteeing a full dose of international attention.   Even though the remaining 30% of respondents likely include some with big recent successes — Bioniche, Allostera and Zymeworks – and some with creative [...]

Monday Deal Review: July 12, 2009

The highlights of this week were definitely the Bioniche-Endo deal and Allostera’s $17 million raise, but that was just the tip of the iceberg as Canadian deal activity heated up along with the weather.  A novel deal with an income trust swapping cash for a biotech’s public shell starts things off

Allocating Spending to Support R&D: UK, U.S. and Canadian Approaches

The U.S., Canada and the UK have all acknowledged the central importance of R&D even in these recessionary times.  However, the three national governments have decided to focus their spending on different steps of the R&D equation: Education: UK Takes the Long View British PM Gordon Brown, in a speech this week, identified three priorities: research, education and training, [...]

Follow

Get every new post delivered to your Inbox.

Join 84 other followers